Pfizer Trying A Novel Oncology Business Unit To Maximize Its Novel Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms that show significant promise. Now the company is trying a novel business arrangement to try to make the most of what it has.